市場調查報告書

腦啡肽酶抑制劑的全球市場 - 各藥物類型·各適應症·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析

Anti-Neprilysin Market, by Drug Type, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

出版商 Coherent Market Insights 商品編碼 968693
出版日期 內容資訊 英文 168 Pages
商品交期: 2-3個工作天內
價格
腦啡肽酶抑制劑的全球市場 - 各藥物類型·各適應症·各流通管道·各地區:市場規模·佔有率·未來展望·機會分析 Anti-Neprilysin Market, by Drug Type, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027
出版日期: 2020年09月09日內容資訊: 英文 168 Pages
簡介

世界各國急性心臟衰竭的患病人數正在增加,因此全球腦啡肽酶抑制劑的市場也相應增長。

本報告提供全球抗腦啡肽酶藥 (腦啡肽酶抑制劑)的市場相關分析,提供產品和相關疾病概要,市場基本結構及促進·阻礙因素,整體市場規模預測 (以金額為準,過去4年·今後8年份),各藥物類型·各適應症·各流通管道·各地區的詳細趨勢,主要企業的簡介·業績·策略計劃等調查。

目錄

第1章 分析目的·前提條件

第2章 市場概要

  • 分析概要
    • 市場定義和範圍
  • 摘要整理
  • COM (Coherent Opportunity Map:市場機會藍圖)

第3章 市場力學·規定·趨勢分析

  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 市場機會
  • 影響度分析
  • 市場趨勢
  • 法規方案
  • 醫療費償付方案
  • 新產品的認證/上市
  • 企業合併·收購 (M&A)
  • 波特的五力分析
  • PEST分析

第4章 全球腦啡肽酶抑制劑市場:COVID-19的影響分析

  • COVID-19以前的市場分析
  • COVID-19以後的市場分析
  • 策略

第5章 全球腦啡肽酶抑制劑市場:各藥物類型

  • 簡介
  • Sacubitril
  • TD-0714
  • STR-324
  • PL-265
  • LHW-090

第6章 全球腦啡肽酶抑制劑市場:各適應症

  • 簡介
  • 急性心臟衰竭
  • 癌症性疼痛
  • 高血壓
  • 阿茲海默症
  • 其他

第7章 全球腦啡肽酶抑制劑市場:各流通管道

  • 簡介
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第8章 全球腦啡肽酶抑制劑市場:各地區

  • 簡介
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 非洲
  • 中東

第9章 競爭情形

  • 企業簡介
    • Bioprojet SCR
    • Novartis International AG
    • Pharmaleads SA
    • Theravance Biopharma Inc.
    • Cipla Limited
    • Oceanic Pharmachem Pvt. Ltd.

第10章 附錄

目錄

Title:
Anti-Neprilysin Market, by Drug Type (Sacubitril, TD-0714, STR-324, PL-265, LHW-090, and Others), by Indication (Acute Heart Failure, Cancer Pain, Hypertension, Alzheimer's Disease, and Others), by Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027.

Anti-neprilysin drugs are majorly used for acute heart failure, cancer pain, hypertension, Alzheimer's disease, and other diseases. Most commonly used anti-neprilysin is Sacubitril/valsartan, which is sold under the brand name, Entrest. It consists of neprilysin inhibitor, sacubitril and the angiotensin receptor blocker, valsartan. Entrest was first manufactured by Novartis International AG in 2015. After the arrival of this drug in the market, there has been a reduction in the rate of cardiovascular deaths and hospitalization related to heart failure. Due to the increasing prevalence of heart failure, the U.S.FDA granted fast track designation to Entresto in 2015, which supports FDA's efforts to facilitate the development and expedite the review of drugs to treat serious or life-threatening conditions and meet unmet medical needs of patients.

Market Dynamics

The increasing prevalence of acute heart failure is expected to highly contribute to the anti-neprilysin market growth over the forecast period. For instance, according to the data published in the Continuing Cardiology Education Journal in 2017, heart failure (HF) is a major public health problem, affecting a total of 26 million people worldwide in 2014. Furthermore, according to the American Heart Association report, the prevalence of acute heart failure in the U.S. in 2012 was 5.7 million, representing 2.2% of the population. The projection is that HF prevalence will increase by 46% by 2030, resulting in over 8 million adults with HF in the U.S. in 2030.

However, the anti-neprilysin market growth is expected to be hampered over the forecast period, owing to the side effects and adverse effects associated with anti-neprilysin drugs. For instance, the drug called Entresto (sacubitril and valsartan), a combination of a neprilysin inhibitor and an angiotensin II receptor blocker, might exhibit serious side effects such as low blood pressure (hypotension), high blood potassium (hyperkalemia), cough, dizziness, and kidney (renal) failure. Such side effects can create life-threating conditions if not consumed under expert supervision.

Key features of the study:

  • This report provides in-depth analysis of the global anti-neprilysin market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global anti-neprilysin market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
  • Key players covered as a part of this study include Bioprojet SCR, Novartis International AG, Pharmaleads SA, Theravance Biopharma Inc., Cipla Limited, and Oceanic Pharmachem Pvt. Ltd.
  • Insights from this report would allow marketers and management authorities of companies to make informed decision with respect to their future product launch, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global anti-neprilysin market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for anti-neprilysin market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Anti-Neprilysin Market, By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
  • Global Anti-Neprilysin Market, By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
  • Global Anti-Neprilysin Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Anti-Neprilysin Market, By Region:
    • North America
      • By Country:
    • U.S.
    • Canada
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Europe
      • By Country:
    • U.K.
    • Germany
    • Italy
    • Spain
    • France
    • Russia
    • Rest of Europe
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Asia Pacific
      • By Country:
    • Australia
    • India
    • China
    • Japan
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Latin America
      • By Country:
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Middle East
      • By Country:
    • GCC
    • Israel
    • Rest of Middle East
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
    • Africa
      • By Country/Region:
    • South Africa
    • Central Africa
    • North Africa
      • By Drug Type:
    • Sacubitril
    • TD-0714
    • STR-324
    • PL-265
    • LHW-090
    • Others
      • By Indication:
    • Acute Heart Failure
    • Cancer Pain
    • Hypertension
    • Alzheimer's Disease
    • Others
      • By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Company Profiles
    • Bioprojet SCR*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Novartis AG
    • Pharmaleads SA
    • Theravance Biopharma Inc.
    • Cipla Limited
    • Oceanic Pharmachem Pvt. Ltd.
  • "*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Overview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Indication
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Market Trends
  • Regulatory Scenario
  • Reimbursement Scenario
  • New Product Launches/Approvals
  • Mergers & Acquisitions
  • Porter's Analysis
  • PEST Analysis

4. Global Anti-Neprilysin Market COVID-19 Impact Analysis

  • Pre-COVID Market Analysis
  • Post - COVID Market Analysis
  • Strategies

5. Global Anti-Neprilysin Market, By Drug Type, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Sacubitril
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • TD-0714
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • STR-324
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • PL-265
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • LHW-090
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

6. Global Anti-Neprilysin Market, By Indication, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Acute Heart Failure
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Cancer Pain
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Hypertension
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Alzheimer's Disease
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Others
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

7. Global Anti-Neprilysin Market, By Distribution Channel, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, 2017 - 2027
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2016 - 2027, (US$ Million)

8. Global Anti-Neprilysin Market, By Region, 2016 - 2027, (US$ Million)

  • Introduction
    • Market Share Analysis, By Region, 2020 and 2027 (%)
    • Y-o-Y Growth Analysis, By Region, 2017 - 2027
    • Regional Trends
  • North America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.S.
    • Canada
  • Europe
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Africa
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country/Region, 2016 - 2027, (US$ Million)
    • North Africa
    • Central Africa
    • South Africa
  • Middle East
    • Market Size and Forecast, By Drug Type, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Indication, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Distribution Channel, 2016 - 2027, (US$ Million)
    • Market Size and Forecast, By Country, 2016 - 2027, (US$ Million)
    • GCC Countries
    • Israel
    • Rest of Middle East

9. Competitive Landscape

  • Company Profiles
    • Bioprojet SCR
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Novartis International AG
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Pharmaleads SA
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Theravance Biopharma Inc.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Cipla Limited
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
    • Oceanic Pharmachem Pvt. Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies

10. Section

  • References
  • Research Methodology
  • About us and Sales Contact